Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00498485 · ClinicalTrials.gov registry record · Phase 4

Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome

A Phase 4 study, sponsored by University of Medicine and Dentistry of New Jersey.

Terminated
Registry status
Phase 4
Development phase
17
Enrollment target

NCT00498485: Clinical Trial Phase 4 study, sponsored by University of Medicine and Dentistry of New Jersey.

NCT00498485 is a Phase 4 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 17 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00498485, a Phase 4 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.

TERMINATED
Registry status
Phase 4
Development phase
17 participants
Enrollment target

Study Summary

Chronic fatigue syndrome is a disabling illness for which there is no specific treatment. As a group, CFS patients have disturbed sleep with frequent arousals and the sense of not having slept upon awakening. Xyrem (Sodium oxybate) is known to improve deep sleep and so may reduce the sleep disturbances of CFS leading to better sleep with less fatigue. Its ability to produce the rapid onset of deep sleep is a reason it became a street drug, but its availability is currently limited via distribution through a single centralized pharmacy. Xyrem has been successfully used based on results from a study on patients with fibromyalgia (FM), an ailment closely resembling CFS. However, in that study, the researchers provided no information as to whether patients had FM alone or FM plus CFS. Thus, it is not clear from this study just which patient may be helped. I have prescribed Xyrem for patients who have both FM and CFS with good results. In this study, funded by the company that makes Xyrem, I propose testing the drug's efficacy on patients with CFS alone - that is, they do not have fibromyalgia. Volunteers for this study will complete paper and pencil questionnaires about their symptoms as well as a computerized test to assess their degree of brain fog. They will then be randomly assigned to one of two groups, placebo or drug. Volunteers will not know what group they are in until the end of the study. Only the drug group will receive the medication. The placebo group will receive a substance that looks identical to the real medicine but with no active ingredients. The medication comes as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will be told to skip taking the second dose. We will call patients weekly to see how they are doing on the "drug." If they have tolerable side effects or report significant im

Primary Outcome

A count was made of subject responses on a Patient Assessment of Change questionnaire where scores went from +2 \[much better\] thru 0 \[no change\] to -2 \[much worse\]

Interventions

  • DRUG Placebo
  • DRUG Sodium Oxybate

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2007-05
Est. Completion 2008-12
Phase Phase 4

Why NCT00498485 stopped before completion

NCT00498485 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00498485 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00498485 about?

NCT00498485 is a clinical study titled "Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome". Chronic fatigue syndrome is a disabling illness for which there is no specific treatment. As a group, CFS patients have disturbed sleep with frequent arousals and the sense of not having slept upon awakening. Xyrem (Sodium oxybate) is known to improve deep sleep and so may reduce the sleep disturban...

What is the current status of trial NCT00498485?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2007-05. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00498485?

The interventions under investigation include: Placebo (DRUG), Sodium Oxybate (DRUG).

Who is sponsoring clinical trial NCT00498485?

This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00498485's enrollment target sits among peer trials

17 1854th of 2000 higher than 132 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00498485, the US trial registry maintained by the National Library of Medicine. NCT00498485 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.